Strategy
The company is trading below cash after admitting that an adverse event in a Rett syndrome trial left a patient critically ill.
Sun and other major Indian firms outline how things are shaping up for products and manufacturing in China - while it’s a mixed bag, the wider outlook is upbeat. M&A and GLP-1 plays were among other key areas discussed during Q2 earnings.
After completing due diligence, private equity firm Brookfield is reportedly close to launching an offer of €10.50 euros per share to acquire the Spanish major. Given that at least one investor believes Grifols is worth at least €20 a share, sparks could fly.
The US firm wants to hook up with the German group to create a global innovative services company but its €11.00 per share cash offer looks unlikely to sway Evotec shareholders.
Yuhan eyes successors to lazertinib after US approval, leadership dispute at Hanmi drags on and SK Bioscience completes CDMO acquisition.
The German major’s CEO Bill Anderson will not be tempted to go out and make a big bid on a late-stage asset to fill the revenue gap caused by Xarelto’s patent expiries, telling Scrip that " in the pharma business, that's pretty much worse than going to the casino.”
At a recent conference, executives from Boehringer and Amgen laid out their expectations for the future of obesity and how they intend to navigate the changes.
The Spanish company's Lilly-partnered atopic dermatitis drug is enjoying a decent launch in Germany and in other European countries, "we are getting the price that we wanted," claims CEO Carlos Gallardo.
Medixci’s Nick Williams told attendees at BIO-Europe that it was a shame that promising biotechs head to the NASDAQ as soon as possible. He and called for a change in culture from investors and for them to back the continent’s start-ups with proper funding.
Novo Nordisk India MD talks to Scrip about what to expect when Wegovy arrives in India and the local trajectory of Rybelsus. The Danish group also shared findings of a study around obesity.
Low prices and intense competition for innovative drugs at home continue to drive Chinese biotechs' globalization. Broader domestic commercial health insurance might provide the key to change.
With Chair Lina Khan expected to exit the commission, the incoming administration may consider elevating one of the Republican commissioners on the panel to succeed her, at least on an acting basis.
The Denmark-based major intends to build on its heritage in diabetes and is keen to hear from innovators in a space where prevalence is on the rise but is not being served by improved new products.
Beyond its cardiovascular partnership with AstraZeneca, Ionis is getting ready to launch antisense drugs for familial chylomicronemia syndrome and hereditary angioedema.
A panel of experts from J&J, UCB and Takeda deliberated on the use of AI and internal processes to strike the right balance between speed and accuracy in MLR reviews that could protect a company from serious repercussions
Emerging Company Profile: Volastra is testing two KIF18A inhibitors in early clinical trials in ovarian cancer, backed by investors like Polaris Partners and ARCH Ventures.
The company, now the most advanced clinically in the psychedelic space after the rejection of Lykos's MDMA-based post-traumatic stress disorder drug, is cutting its workforce by a third and narrowing its research focus after shifting the timeline for its late-stage depression candidate.
Uptake in immunology, gastrointestinal and dermatology indications have enabled Skyrizi to post 51% year-over-year growth, and overtake sales for biosimilar-challenged stalwart Humira.
As it posts third-quarter numbers that again reveal the decline of revenues from its multiple sclerosis portfolio, the US biotech major is entering into the hot area of targeted protein degradation to boost its immunology and neurology pipeline.
CEO Albert Bourla said Starboard Value’s push for change at Pfizer is coming 15 months late as the company is already executing a five-point plan to cut costs and pivot on strategy.